Načítá se...
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies
Advances in cancer therapy in the past few years have include the development of medications that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed death 1 (PD1), are two coinhibitory receptors that are expressed on activated T cells to which therapeutic bl...
Uloženo v:
| Vydáno v: | Nat Rev Endocrinol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5629093/ https://ncbi.nlm.nih.gov/pubmed/28106152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrendo.2016.205 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|